MA29260B1 - Derives d'oxindole servant d'agonistes du recepteur 5ht4 - Google Patents
Derives d'oxindole servant d'agonistes du recepteur 5ht4Info
- Publication number
- MA29260B1 MA29260B1 MA30153A MA30153A MA29260B1 MA 29260 B1 MA29260 B1 MA 29260B1 MA 30153 A MA30153 A MA 30153A MA 30153 A MA30153 A MA 30153A MA 29260 B1 MA29260 B1 MA 29260B1
- Authority
- MA
- Morocco
- Prior art keywords
- disease
- gastric
- dyspepsy
- oeso
- compounds
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 title abstract 2
- 150000005623 oxindoles Chemical class 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000012895 Gastric disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 206010030216 Oesophagitis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000006549 dyspepsia Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000006881 esophagitis Diseases 0.000 abstract 1
- 230000030135 gastric motility Effects 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I) OU UN DE LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES OÙ : A, R1, R2, R3, R4 ET R5 SONT DÉCRITS DANS LA DESCRIPTION, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, ET DES COMPOSITIONS CONTENANT CES COMPOSÉS AINSI QUE LEUR UTILISATION DANS LE TRAITEMENT D'UN ÉTAT À MÉDIATION PAR UNE ACTIVITÉ DE RÉCEPTEUR 5-HT4 TEL QUE (MAIS DE FAÇON NON RESTRICTIVE) LE REFLUX OESO-GASTRIQUE, LA MALADIE GASTRO-INTESTINALE, LE TROUBLE DE MOTILITÉ GASTRIQUE, LA DYSPEPSIE NON ULCÉREUSE, LA DYSPEPSIE FONCTIONNELLE, LE SYNDROME DU CÔLON IRRITABLE (IBS), LA CONSTIPATION, LA DYSPEPSIE, L'OESOPHAGITE, LA MALADIE OESO-GASTRIQUE, LA NAUSÉE, LA MALADIE DU SYSTÈME NERVEUX CENTRAL, LA MALADIE D'ALZHEIMER, LE TROUBLE COGNITIF, LE VOMISSEMENT, LA MIGRAINE, LE TROUBLE NEUROLOGIQUE, LA DOULEUR, LES TROUBLES CARDIOVASCULAIRES, L'INSUFFISANCE CARDIAQUE, L'ARYTHMIE, LE DIABÈTE ET LE SYNDROME D'APNÉE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65527605P | 2005-02-22 | 2005-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29260B1 true MA29260B1 (fr) | 2008-02-01 |
Family
ID=36579484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30153A MA29260B1 (fr) | 2005-02-22 | 2007-08-22 | Derives d'oxindole servant d'agonistes du recepteur 5ht4 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7589109B2 (fr) |
| EP (1) | EP1856110B1 (fr) |
| JP (1) | JP4130220B1 (fr) |
| KR (1) | KR100908547B1 (fr) |
| CN (1) | CN101522668B (fr) |
| AP (1) | AP2007004067A0 (fr) |
| AR (1) | AR053548A1 (fr) |
| AT (1) | ATE513827T1 (fr) |
| AU (1) | AU2006217534B8 (fr) |
| BR (1) | BRPI0607456A2 (fr) |
| CA (1) | CA2598536C (fr) |
| DK (1) | DK1856110T3 (fr) |
| DO (1) | DOP2006000046A (fr) |
| EA (1) | EA012615B1 (fr) |
| ES (1) | ES2366375T3 (fr) |
| GE (1) | GEP20094727B (fr) |
| GT (1) | GT200600083A (fr) |
| HN (1) | HN2006007884A (fr) |
| IL (1) | IL184505A0 (fr) |
| MA (1) | MA29260B1 (fr) |
| MX (1) | MX2007010139A (fr) |
| NL (1) | NL1031218C2 (fr) |
| NO (1) | NO20073566L (fr) |
| NZ (1) | NZ556627A (fr) |
| PE (1) | PE20061096A1 (fr) |
| TN (1) | TNSN07319A1 (fr) |
| TW (1) | TW200640915A (fr) |
| UA (1) | UA86301C2 (fr) |
| UY (1) | UY29389A1 (fr) |
| WO (1) | WO2006090279A1 (fr) |
| ZA (1) | ZA200706420B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1094757C (zh) | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物 |
| AP2007004067A0 (en) * | 2005-02-22 | 2007-08-31 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
| US8501773B2 (en) * | 2005-06-29 | 2013-08-06 | Merck Sharp & Dohme Corp. | 4-fluoro-piperidine T-type calcium channel antagonists |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| WO2007086559A1 (fr) * | 2006-01-27 | 2007-08-02 | Ube Industries, Ltd. | Procede de fabrication d'un compose tetrahydropyrane |
| WO2008021422A2 (fr) * | 2006-08-17 | 2008-02-21 | Wyeth | Procédé de préparation de dérivés d'indolin-2-one servant de modulateurs du récepteur de la progestérone |
| KR101697773B1 (ko) * | 2008-03-10 | 2017-01-18 | 유로드러그 레버러토리즈 비. 브이. | 독소필린을 포함하는 변형 방출 조성물 |
| US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| WO2010098145A1 (fr) * | 2009-02-27 | 2010-09-02 | Raqualia Pharma Inc. | Dérivés d'oxyindole ayant une activité agoniste au récepteur de la motiline |
| CN102421288B (zh) * | 2009-05-07 | 2015-04-22 | 联合治疗公司 | 前列环素类似物的固体剂型 |
| WO2011030349A1 (fr) | 2009-09-14 | 2011-03-17 | Suven Life Sciences Limited | Composés de 1,2-dihydro-2-oxoquinoléine comme ligands des récepteurs 5-ht4 |
| CN107260736A (zh) * | 2010-02-12 | 2017-10-20 | 株式会社ＡｓｋＡｔ | 用于治疗痴呆的5‑ht4受体激动剂 |
| MX337721B (es) | 2011-09-19 | 2016-03-16 | Suven Life Sciences Ltd | Compuestos de heteroarilo como ligandos del receptor 5-ht4. |
| KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| MY183499A (en) | 2014-02-13 | 2021-02-22 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| CR20160395A (es) | 2014-02-13 | 2016-12-20 | Incyte Corp | Ciclopropilaminas como inhibidores de lsd1 |
| ES2672797T3 (es) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Ciclopropilaminas como inhibidores de LSD1 |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| MA51438A (fr) | 2015-04-03 | 2021-04-14 | Incyte Corp | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 |
| SG10202001219UA (en) * | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
| JP7030720B2 (ja) * | 2016-02-16 | 2022-03-07 | ストロングブリッジ ダブリン リミテッド | 先端巨大症、先端巨大症がん、ｓｓｔ－ｒ５発現腫瘍、２型糖尿病、高血糖症、及びホルモン関連腫瘍の治療において使用するための、生理学的条件において難溶性であるベルドレオチド |
| CR20180553A (es) | 2016-04-22 | 2019-02-01 | Incyte Corp | Formulaciones de un inhibidor de lsd1 |
| WO2020047198A1 (fr) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Sels d'un inhibiteur de lsd1 et leurs procédés de préparation |
| CN114105863B (zh) * | 2021-12-07 | 2023-11-28 | 江苏汉拓光学材料有限公司 | 酸扩散抑制剂、含酸扩散抑制剂的化学放大型光刻胶及其制备与使用方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552408A (en) | 1987-09-23 | 1996-09-03 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists |
| US5223511A (en) | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
| GB8829079D0 (en) | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
| GB9020927D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Pharmaceuticals |
| JPH06506443A (ja) | 1991-01-09 | 1994-07-21 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アザ二環式およびアザ三環式誘導体、その製法および中間体ならびに該化合物含有の医薬組成物 |
| US5955470A (en) | 1991-06-11 | 1999-09-21 | Merrell Pharmaceuticals, Inc. | Derivatives of amide analogs of certain methano bridged quinolizines |
| IT1251144B (it) | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| GB9121170D0 (en) | 1991-10-05 | 1991-11-20 | Smithkline Beecham Plc | Pharmaceuticals |
| GB9204565D0 (en) * | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
| US5300512A (en) | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
| US5280028A (en) | 1992-06-24 | 1994-01-18 | G. D. Searle & Co. | Benzimidazole compounds |
| US5521193A (en) | 1992-06-24 | 1996-05-28 | G. D. Searle & Co. | Benzimidazole compounds |
| FR2694292B1 (fr) | 1992-07-29 | 1994-10-21 | Esteve Labor Dr | Dérivés de benzimidazole-2-thione-, leur préparation et leur application en tant que médicament. |
| US5705498A (en) | 1992-11-05 | 1998-01-06 | Smithkline Beecham Plc. | Piperidine derivatives as 5-HT4 receptor antagonists |
| TW251287B (fr) | 1993-04-30 | 1995-07-11 | Nissei Co Ltd | |
| GB9312348D0 (en) | 1993-06-16 | 1993-07-28 | Smithkline Beecham Plc | Pharmaceuticals |
| US5534521A (en) | 1993-06-23 | 1996-07-09 | G. D. Searle & Co. | Benzimidazole compounds |
| CA2134192A1 (fr) | 1993-11-12 | 1995-05-13 | Michael L. Denney | Antagonistes iib/iiia de la glycoproteine 5, 6-bicyclique |
| US5399562A (en) * | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
| GB9414139D0 (en) | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
| DE4440675A1 (de) | 1994-11-14 | 1996-05-15 | Basf Ag | Verfahren zur Herstellung von kautschukmodifizierten Formmassen mittels in den Kautschuk eingebauten, bei thermischer Zersetzung Radikale bildenden Gruppen |
| IT1275903B1 (it) | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| EP1015429B1 (fr) | 1997-09-09 | 2004-05-12 | Bristol-Myers Squibb Pharma Company | BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES ET LEURS DERIVES EN TANT QU'INHIBITEURS DU FACTEUR Xa |
| US6069152A (en) | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6310059B1 (en) | 1998-06-30 | 2001-10-30 | Neuromed Technologies, Inc. | Fused ring calcium channel blockers |
| US6492375B2 (en) | 1998-06-30 | 2002-12-10 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
| AU1707700A (en) | 1998-10-29 | 2000-05-22 | Bristol-Myers Squibb Company | Novel inhibitors of impdh enzyme |
| JP2003518107A (ja) | 1999-12-20 | 2003-06-03 | ニューロメド テクノロジーズ， インコーポレイテッド | 部分飽和カルシウムチャネルブロッカー |
| WO2002030886A2 (fr) | 2000-10-12 | 2002-04-18 | Matthews Barry R | Inhibiteurs d'angiogenese heterocycliques |
| AU2002239508B9 (en) | 2000-12-07 | 2005-09-08 | Gilead Palo Alto, Inc. | Substituted 1, 3, 5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis |
| DOP2003000703A (es) * | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| EP1637521B1 (fr) | 2003-06-23 | 2013-06-19 | Ono Pharmaceutical Co., Ltd. | Nouveau compose heterocyclique tricyclique |
| DK1664036T3 (da) | 2003-09-03 | 2012-02-13 | Pfizer | Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning |
| EP1758891A2 (fr) | 2004-06-15 | 2007-03-07 | Pfizer Japan Inc. | Derives de benzimidazolone d'acide carboxylique |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| AP2007004067A0 (en) * | 2005-02-22 | 2007-08-31 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
-
2006
- 2006-02-10 AP AP2007004067A patent/AP2007004067A0/xx unknown
- 2006-02-10 CN CN200680005786XA patent/CN101522668B/zh not_active Expired - Fee Related
- 2006-02-10 JP JP2007556683A patent/JP4130220B1/ja not_active Expired - Fee Related
- 2006-02-10 NZ NZ556627A patent/NZ556627A/en not_active IP Right Cessation
- 2006-02-10 BR BRPI0607456-1A patent/BRPI0607456A2/pt not_active IP Right Cessation
- 2006-02-10 DK DK06710525.4T patent/DK1856110T3/da active
- 2006-02-10 MX MX2007010139A patent/MX2007010139A/es active IP Right Grant
- 2006-02-10 EA EA200701552A patent/EA012615B1/ru not_active IP Right Cessation
- 2006-02-10 EP EP06710525A patent/EP1856110B1/fr not_active Expired - Lifetime
- 2006-02-10 GE GEAP200610234A patent/GEP20094727B/en unknown
- 2006-02-10 CA CA2598536A patent/CA2598536C/fr not_active Expired - Fee Related
- 2006-02-10 WO PCT/IB2006/000519 patent/WO2006090279A1/fr not_active Ceased
- 2006-02-10 AT AT06710525T patent/ATE513827T1/de not_active IP Right Cessation
- 2006-02-10 ES ES06710525T patent/ES2366375T3/es not_active Expired - Lifetime
- 2006-02-10 KR KR1020077019124A patent/KR100908547B1/ko not_active Expired - Fee Related
- 2006-02-10 AU AU2006217534A patent/AU2006217534B8/en not_active Ceased
- 2006-02-20 DO DO2006000046A patent/DOP2006000046A/es unknown
- 2006-02-20 PE PE2006000207A patent/PE20061096A1/es not_active Application Discontinuation
- 2006-02-20 AR ARP060100601A patent/AR053548A1/es unknown
- 2006-02-21 HN HN2006007884A patent/HN2006007884A/es unknown
- 2006-02-21 TW TW095105776A patent/TW200640915A/zh unknown
- 2006-02-21 GT GT200600083A patent/GT200600083A/es unknown
- 2006-02-22 UY UY29389A patent/UY29389A1/es not_active Application Discontinuation
- 2006-02-22 NL NL1031218A patent/NL1031218C2/nl not_active IP Right Cessation
- 2006-02-22 US US11/360,095 patent/US7589109B2/en not_active Expired - Fee Related
- 2006-10-02 UA UAA200709522A patent/UA86301C2/uk unknown
-
2007
- 2007-07-09 IL IL184505A patent/IL184505A0/en unknown
- 2007-07-10 NO NO20073566A patent/NO20073566L/no not_active Application Discontinuation
- 2007-08-01 ZA ZA200706420A patent/ZA200706420B/xx unknown
- 2007-08-21 TN TNP2007000319A patent/TNSN07319A1/fr unknown
- 2007-08-22 MA MA30153A patent/MA29260B1/fr unknown
-
2009
- 2009-06-24 US US12/490,451 patent/US20100173925A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29260B1 (fr) | Derives d'oxindole servant d'agonistes du recepteur 5ht4 | |
| MA28021A1 (fr) | Dérivés de benzimidazolone à activité agoniste des récepteurs 5-HT4 | |
| UY29421A1 (es) | Nuevos compuestos de n-(n-sulfonilaminoarilmetil) ciclopropanocarboxanida sustituidos, comoposiciones farmacéuticas que los contienen a aplicaciones. | |
| EA200602122A1 (ru) | Производные бензимидазолонкарбоновой кислоты | |
| JP4091648B2 (ja) | ２−（１ｈ−インドリルスルファニル）−ベンジルアミン誘導体 | |
| ATE449092T1 (de) | Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors | |
| ZA200600427B (en) | 1-sulfonylindole derivatives, their preparation and their use as 5-HT6 ligands | |
| ES2202348T3 (es) | Derivados del azabicicloheptano n-substituidos, como por ejemplo neurolepticos. | |
| CZ282054B6 (cs) | 1-/Pyrido/3,4-b/-1,4-oxazin-4-yl/-1H-indoly, meziprodukty a způsob jejich přípravy a jejich použití jako léčiv | |
| CZ287862B6 (en) | N-substituted 3-azabicyclo[3.2.0]heptane derivatives, process of their preparation and use | |
| US20060183902A1 (en) | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | |
| RU2120439C1 (ru) | N-замещенные производные 3-азабицикло(3,2,0)-гептана и их соли с физиологически переносимыми кислотами | |
| TH76314A (th) | สารอนุพันธ์แบบซิมิดาโซโลน คาร์บอกซิลิก แอซิด | |
| US7235568B2 (en) | 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | |
| TH81015B (th) | อนุพันธ์ออกซิอินโดล | |
| CA2176962C (fr) | Derives d'azabicycloheptane avec substituant sur l'atome d'azote, leur preparation et leur utilisation | |
| TH106943A (th) | สารประกอบเบนซิมิดาโซโลนที่มีแอคทิวิทีต่อต้าน 5-ht4 รีเซพเตอร์ |